Pfizer Inc. which can be found using ticker (PFE) have now 21 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $50.00 and $23.00 suggesting an average Analsyt target price of $32.33. Given that the stocks previous close was at $27.91 this would indicate that there is a potential upside of 15.8%. There is a 50 day moving average of $28.85 and the 200 day MA is $34.13. The total market capitalization for the company now stands at 155.11B. The current share price for the company is: $27.47 USD
The potential market cap would be $179,670,570,136 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 15.01, revenue per share of $12.16 and a 5.39% return on assets.
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.
